These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 10597204)

  • 21. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.
    Fosså SD; Kaye SB; Mead GM; Cullen M; de Wit R; Bodrogi I; van Groeningen CJ; De Mulder PH; Stenning S; Lallemand E; De Prijck L; Collette L
    J Clin Oncol; 1998 Feb; 16(2):716-24. PubMed ID: 9469362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors.
    Bokemeyer C; Köhrmann O; Tischler J; Weissbach L; Räth U; Haupt A; Schöffski P; Harstrick A; Schmoll HJ
    Ann Oncol; 1996 Dec; 7(10):1015-21. PubMed ID: 9037359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948).
    Fosså SD; Paluchowska B; Horwich A; Kaiser G; de Mulder PH; Koriakine O; van Oosterom AT; de Prijck L; Collette L; de Wit R;
    Br J Cancer; 2005 Nov; 93(11):1209-14. PubMed ID: 16251877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
    Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
    Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paclitaxel in salvage therapy for germ cell tumors.
    Motzer RJ
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-83-S15-85. PubMed ID: 9346229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).
    Huddart RA; Gabe R; Cafferty FH; Pollock P; White JD; Shamash J; Cullen MH; Stenning SP; ;
    Eur Urol; 2015 Mar; 67(3):534-43. PubMed ID: 25001888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group.
    Toner GC; Stockler MR; Boyer MJ; Jones M; Thomson DB; Harvey VJ; Olver IN; Dhillon H; McMullen A; Gebski VJ; Levi JA; Simes RJ
    Lancet; 2001 Mar; 357(9258):739-45. PubMed ID: 11253966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncological outcomes of metastatic testicular cancers under centralized management through regional medical network.
    Inai H; Kawai K; Kojima T; Joraku A; Shimazui T; Yamauchi A; Miyagawa T; Endo T; Fukuhara Y; Miyazaki J; Uchida K; Nishiyama H
    Jpn J Clin Oncol; 2013 Dec; 43(12):1249-54. PubMed ID: 24101656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment in germ cell tumours: state of the art.
    Tjan-Heijnen VC; Oosterhof GO; de Wit R; De Mulder PH
    Eur J Surg Oncol; 1997 Apr; 23(2):110-7. PubMed ID: 9158183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial.
    Mead GM; Cullen MH; Huddart R; Harper P; Rustin GJ; Cook PA; Stenning SP; Mason M;
    Br J Cancer; 2005 Jul; 93(2):178-84. PubMed ID: 15999102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [International study on testicular cancer: EORTC 30983: randomized phase II/III study of Taxol-BEP versus BEP in patients with Intermediate Prognosis Germ Cell Cancer].
    Rexer FH
    Urologe A; 2005 Sep; 44(9):1064-5. PubMed ID: 16265725
    [No Abstract]   [Full Text] [Related]  

  • 32. [Treatment of metastatic testicular carcinoma according to prognosis; new development].
    de Wit R; Stoter G
    Ned Tijdschr Geneeskd; 2001 Jun; 145(25):1194-9. PubMed ID: 11447874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion.
    Chevreau C; Mazerolles C; Soulié M; Gaspard MH; Mourey L; Bujan L; Plante P; Rischmann P; Bachaud JM; Malavaud B
    Eur Urol; 2004 Aug; 46(2):209-14; discussion 214-5. PubMed ID: 15245815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II trial of VP-16, ifosfamide, cisplatin, vinblastine, and bleomycin in advanced germ-cell tumors.
    Blanke C; Loehrer PJ; Nichols CR; Einhorn LH
    Am J Clin Oncol; 1996 Oct; 19(5):487-91. PubMed ID: 8823477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20).
    Fosså SD; de Wit R; Roberts JT; Wilkinson PM; de Mulder PH; Mead GM; Cook P; de Prijck L; Stenning S; Aaronson NK; Bottomley A; Collette L; ;
    J Clin Oncol; 2003 Mar; 21(6):1107-18. PubMed ID: 12637478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour.
    Rimmer Y; Chester J; Joffe J; Stark D; Shamash J; Powles T; White J; Wason J; Parashar D; Armstrong G; Mazhar D; Williams MV
    Br J Cancer; 2011 Sep; 105(6):766-72. PubMed ID: 21847130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.
    Lotz JP; André T; Donsimoni R; Firmin C; Bouleuc C; Bonnak H; Merad Z; Esteso A; Gerota J; Izrael V
    Cancer; 1995 Feb; 75(3):874-85. PubMed ID: 7828139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
    Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
    J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council.
    de Wit R; Roberts JT; Wilkinson PM; de Mulder PH; Mead GM; Fosså SD; Cook P; de Prijck L; Stenning S; Collette L
    J Clin Oncol; 2001 Mar; 19(6):1629-40. PubMed ID: 11250991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
    Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
    J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.